Dr. Infante joined Janssen in June 2017 as the Vice President, Early Development, Oncology. He leads a team of physicians and scientists that design and conduct all the early phase cancer trials These trials span across all the disease area strongholds and range from first-in-human through proof-of-relevance. The early development team is also responsible for combination dose finding trials and all the clinical pharmacology studies that accompany our approved assets and those in registration.
Before Janssen, Dr. Infante spent over a decade at the Sarah Cannon Research Institute as a clinical investigator and board certified medical oncologist. During his tenure, he served many roles, including Director, Drug Development Program where he provided physician leadership to the Drug Development Units in Nashville, Florida, Oklahoma, Denver, and London. He has expertise with multiple novel treatment platforms and has helped design and conduct many clinical studies ranging from first-in-human dosing through phase 3 registration trials.
Dr. Infante received his undergraduate and medical degrees from the University of Florida in 1994 and 1999, respectively, and finished his internal medicine residency at Parkland Memorial Hospital, University of Texas Southwestern Medical Center. He completed his fellowship in medical oncology at Johns Hopkins University School of Medicine in 2006. Concurrent with his fellowship, he undertook formal training in patient-oriented research and received a master of health science degree in epidemiology at Johns Hopkins University’s Bloomberg School of Public Health.